Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lambert Assoumou

Showing results (1-10 of 123) with videos related to

Pageof 13
Sort By:
Sante Publique (Vandoeuvre-Les-Nancy, France)|February 4, 2017
Is gender a factor associated with initiation of antiretroviral therapy at the Ambulatory Treatment Centre of Brazzaville?Martin Herbas Ekat, Lambert Assoumou, Merlin Diafouka
The Journal of Antimicrobial Chemotherapy|February 19, 2010
Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosineLambert Assoumou, Allal Houssaïni, Dominique Costagliola, et al.
Plos One|April 5, 2013
Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation setAllal Houssaini, Lambert Assoumou, Veronica Miller, et al.
The Open AIDS Journal|December 20, 2016
Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in FranceIsabelle Funck-Brentano, Lambert Assoumou, Florence Veber, et al.
AIDS Research and Treatment|May 3, 2012
Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial DataAllal Houssaïni, Lambert Assoumou, Anne Geneviève Marcelin, et al.
AIDS (London, England)|August 14, 2018
Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencingStéphanie Raymond, Constance Delaugerre, Florence Nicot, et al.
AIDS (London, England)|April 14, 2009
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patientsClaudine Duvivier, Sami Kolta, Lambert Assoumou, et al.
AIDS (London, England)|September 11, 2015
A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral controlLambert Assoumou, Laurence Weiss, Christophe Piketty, et al.
AIDS (London, England)|May 21, 2014
T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infectionLaurence Weiss, Mathieu F Chevalier, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2016
HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimensPierre Gantner, Lambert Assoumou, Marianne Leruez-Ville, et al.
Pageof 13

Showing results (1-10 of 123) with videos related to

Sort By:
Pageof 13
Sante Publique (Vandoeuvre-Les-Nancy, France)|February 4, 2017
Is gender a factor associated with initiation of antiretroviral therapy at the Ambulatory Treatment Centre of Brazzaville?Martin Herbas Ekat, Lambert Assoumou, Merlin Diafouka
The Journal of Antimicrobial Chemotherapy|February 19, 2010
Relative contributions of baseline patient characteristics and the choice of statistical methods to the variability of genotypic resistance scores: the example of didanosineLambert Assoumou, Allal Houssaïni, Dominique Costagliola, et al.
Plos One|April 5, 2013
Scoring methods for building genotypic scores: an application to didanosine resistance in a large derivation setAllal Houssaini, Lambert Assoumou, Veronica Miller, et al.
The Open AIDS Journal|December 20, 2016
Resilience and Life Expectations of Perinatally HIV-1 Infected Adolescents in FranceIsabelle Funck-Brentano, Lambert Assoumou, Florence Veber, et al.
AIDS Research and Treatment|May 3, 2012
Investigation of Super Learner Methodology on HIV-1 Small Sample: Application on Jaguar Trial DataAllal Houssaïni, Lambert Assoumou, Anne Geneviève Marcelin, et al.
AIDS (London, England)|August 14, 2018
Accurate quantification of CXCR4-using HIV-1 variants by Illumina deep-sequencingStéphanie Raymond, Constance Delaugerre, Florence Nicot, et al.
AIDS (London, England)|April 14, 2009
Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patientsClaudine Duvivier, Sami Kolta, Lambert Assoumou, et al.
AIDS (London, England)|September 11, 2015
A low HIV-DNA level in peripheral blood mononuclear cells at antiretroviral treatment interruption predicts a higher probability of maintaining viral controlLambert Assoumou, Laurence Weiss, Christophe Piketty, et al.
AIDS (London, England)|May 21, 2014
T-cell activation positively correlates with cell-associated HIV-DNA level in viremic patients with primary or chronic HIV-1 infectionLaurence Weiss, Mathieu F Chevalier, Lambert Assoumou, et al.
The Journal of Antimicrobial Chemotherapy|July 20, 2016
HIV-1-RNA in seminal plasma correlates with detection of HIV-1-DNA in semen cells, but not with CMV shedding, among MSM on successful antiretroviral regimensPierre Gantner, Lambert Assoumou, Marianne Leruez-Ville, et al.
Pageof 13